[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100447248":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":36,"collaborators":7,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":7,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":7,"enrollmentInfo":47,"targetDuration":7,"studyType":50,"phases":7,"briefSummary":51,"conditions":52,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"Federation Francophone de Cancerologie Digestive","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Rosine GUIMBAUD, PhD.MD","Fédération francophone de Cancérologie digestive","PRINCIPAL_INVESTIGATOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"ROSINE GUIMBAUD, PhD.MD","CONTACT","+33 (0)5 61 32 21 42","guimbaud.r@chu-toulouse.fr",[20],{"facility":21,"status":22,"city":23,"state":7,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"CHU -hopital Rangeuil","RECRUITING","Toulouse","31059","France","FR",{"type":28,"coordinates":29},"Point",[30,31],1.44367,43.60426,{"lat":31,"lon":30},[34],{"name":35,"role":16,"phone":17,"phoneExt":7,"email":18},"Rosine GUIMBAUD, PhD MD",{"type":37,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100447248","cohort-of-tumors-with-poled1-mutation-100447248",false,"NCT05103969","Cohort of Tumors With POLE\u002FD1 Mutation","Multicenter Prospective Cohort of Tumors With Pole\u002FD1 Mutation","Inclusion Criteria:\n\n* Any tumor presenting a variant of the exonuclease domain of POLE (exons 9 to 14) classified as pathogenic by the project working group, including: the 4 hotspots of mutations described (codons 286 (P286R\u002FH\u002FL), 411 (V411L), 459 (S459F), 424 (L424\u002FV\u002FI), (2).\n* Any tumor presenting a variant of the exonuclease domain of PolD1 (exons 8-12), classified as pathogenic by the project working group, including : C319Y(10).\n\nDiagnosis made from the date of launch of the cohort and in the previous year\n\n-Age ≥ 18 years\n\nExclusion Criteria:\n\n* Tumor without POLE or POLD1 mutation\n* Tumor with POLE mutation identified in research studies retrospective research\n* Opposition of the patient to the registration of his data in the cohort","ALL","18 Years",{"count":48,"type":49},100,"ESTIMATED","OBSERVATIONAL","Primary objective of this study is to identify and describe the clinico-biological and molecular characteristics of tumors with somatic POLE (Polymerase ɛ)\u002FPOLD1 mutation identified by molecular biology platforms for all stages and primary sites combined",[53,54,55],"Tumors","POLE Exonuclease Domain Mutation","POLD1 Gene Mutation","2024-07-05",{"date":58,"type":59},"2024-07-08","ACTUAL",{"date":61,"type":59},"2021-10-05",{"date":63,"type":49},"2025-10-06",{"name":5,"class":6},1]